Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -114.53% is 59% below its 5-year average of -72.21%, around the middle of its 5-year range (-187.19%–-27.33%).
6.78% below its 12-month average of -107.26%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -2.27%.
RETURN ON ASSETS (ROA)
-114.53%
RETURN ON ASSETS (ROA) AVG TTM
-107.26%
RETURN ON ASSETS (ROA) AVG 3Y
-84.46%
RETURN ON ASSETS (ROA) AVG 5Y
-72.21%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-6.78%
CURRENT VS 3Y AVG
-35.60%
CURRENT VS 5Y AVG
-58.60%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-23.23%
median of 384 covered companies
CURRENT VS SECTOR MEDIAN
-393.13%
vs the sector median at left
Aligos Therapeutics, Inc.
Market Cap
$33.42M
Return on Assets (ROA)
-114.53%
TTM Avg
-107.26%
3Y Avg
-84.46%
5Y Avg
-72.21%
Market Cap
$32.32M
Return on Assets (ROA)
-45.77%
TTM Avg
-31.61%
3Y Avg
-54.99%
5Y Avg
-58.45%
Market Cap
$32.31M
Return on Assets (ROA)
-277.36%
TTM Avg
-524.61%
3Y Avg
-478.10%
5Y Avg
-316.43%
Market Cap
$31.36M
Return on Assets (ROA)
-39.14%
TTM Avg
-11.59%
3Y Avg
6.23%
5Y Avg
18.56%
Market Cap
$35.89M
Return on Assets (ROA)
-11.09%
TTM Avg
-5.71%
3Y Avg
-4.17%
5Y Avg
-3.19%
Market Cap
$30.92M
Return on Assets (ROA)
-99.62%
TTM Avg
-39.99%
3Y Avg
-67.06%
5Y Avg
188.84%
Market Cap
$36.05M
Return on Assets (ROA)
-103.00%
TTM Avg
-39.81%
3Y Avg
-17.36%
5Y Avg
-12.69%
Market Cap
$30.65M
Return on Assets (ROA)
-116.76%
TTM Avg
-76.53%
3Y Avg
-78.60%
5Y Avg
-71.54%
Market Cap
$36.31M
Return on Assets (ROA)
-190.81%
TTM Avg
-476.65%
3Y Avg
-339.92%
5Y Avg
-580.90%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | $33.42M | -114.53% | -107.26% | -84.46% | -72.21% |
| BeyondSpring Inc. (BYSI)vs › | $32.32M | -45.77% | -31.61% | -54.99% | -58.45% |
| EUDA Health Holdings Limited (EUDA)vs › | $32.31M | -277.36% | -524.61% | -478.10% | -316.43% |
| Baird Medical Investment Holdings Limited (BDMD)vs › | $31.36M | -39.14% | -11.59% | 6.23% | 18.56% |
| Accuray Incorporated (ARAY)vs › | $35.89M | -11.09% | -5.71% | -4.17% | -3.19% |
| Context Therapeutics Inc. (CNTX)vs › | $30.92M | -99.62% | -39.99% | -67.06% | 188.84% |
| DocGo Inc. (DCGO)vs › | $36.05M | -103.00% | -39.81% | -17.36% | -12.69% |
| CervoMed Inc. (CRVO)vs › | $30.65M | -116.76% | -76.53% | -78.60% | -71.54% |
| HeartBeam, Inc. (BEAT)vs › | $36.31M | -190.81% | -476.65% | -339.92% | -580.90% |
| Elutia Inc (ELUT)vs › | $36.32M | 118.69% | -31.86% | -49.56% | -43.59% |
ROA
-114.5%
ROE
-238.2%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -27.33% |
| 2024-12-31 | -187.19% |
| 2023-12-31 | -57.86% |
| 2022-12-31 | -65.47% |
| 2021-12-31 | -54.52% |
| 2020-12-31 | -40.91% |
| 2019-12-31 | -35.67% |
| 2018-12-31 | -12.93% |
